Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
24.00
+1.86 (8.40%)
Oct 20, 2026, 10:36 AM EDT - Market open
Arcus Biosciences Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Arcus Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $40. The average 1-year stock price forecast is 66.67% higher than the current stock price, while the lowest is $23 (-4.17%) and the highest is $47 (+95.83%).
Price Target: $40 (+66.67%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Arcus Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 10 | 10 | 11 | 11 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 3 | 3 | 3 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Maintains $42 | Buy | Maintains | $42 | +75.00% | Oct 19, 2026 |
Unknown Analyst William Blair No rating | William Blair | Buy Initiates $410 → $50 | Buy | Initiates | $410 → $50 | +108.33% | Oct 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Initiates $41 | Buy | Initiates | $41 | +70.83% | Oct 14, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains $29 | Hold | Maintains | $29 | +20.83% | Oct 5, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $46 | Buy | Maintains | $46 | +91.67% | Oct 3, 2026 |
Financial Forecast
Revenue This Year
74.72M
from 247.00M
Decreased by -69.75%
Revenue Next Year
60.89M
from 74.72M
Decreased by -18.51%
EPS This Year
-3.58
from -3.29
EPS Next Year
-3.20
from -3.58
EPS and Forward PE are based on non-GAAP adjusted numbers.